Joensuu J J, Niklander-Teeri V, Brandle J E
1Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland.
2Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3.
Phytochem Rev. 2008;7(3):553-577. doi: 10.1007/s11101-008-9088-2. Epub 2008 Mar 8.
A variety of plant species have been genetically modified to accumulate vaccine antigens for human and animal health and the first vaccine candidates are approaching the market. The regulatory burden for animal vaccines is less than that for human use and this has attracted the attention of researchers and companies, and investment in plant-made vaccines for animal infectious disease control is increasing. The dosage cost of vaccines for animal infectious diseases must be kept to a minimum, especially for non-lethal diseases that diminish animal welfare and growth, so efficient and economic production, storage and delivery are critical for commercialization. It has become clear that transgenic plants are an economic and efficient alternative to fermentation for large-scale production of vaccine antigens. The oral delivery of plant-made vaccines is particularly attractive since the expensive purification step can be avoided further reducing the cost per dose. This review covers the current status of plant-produced vaccines for the prevention of disease in animals and focuses on barriers to the development of such products and methods to overcome them.
多种植物物种已通过基因改造来积累用于人类和动物健康的疫苗抗原，首批候选疫苗正逐步走向市场。动物疫苗的监管负担小于人用疫苗，这吸引了研究人员和公司的关注，对用于动物传染病防控的植物源疫苗的投资也在增加。动物传染病疫苗的剂量成本必须降至最低，尤其是对于那些会降低动物福利和生长的非致命性疾病，因此高效且经济的生产、储存和递送对于商业化至关重要。很明显，转基因植物是大规模生产疫苗抗原的一种经济高效的发酵替代方法。植物源疫苗的口服给药尤其具有吸引力，因为可以避免昂贵的纯化步骤，进一步降低每剂成本。本综述涵盖了用于预防动物疾病的植物生产疫苗的现状，并重点关注此类产品开发的障碍及克服这些障碍的方法。
